Back

High-protein diet ameliorates anthracycline-induced cardiotoxicity in mice

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Targeting metabolism in heart failure Cardiotoxicity of Drugs and Other Therapies ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Miss Anabel Diaz-Guerra Priego

Madrid (Spain)

7 More presentations in this session

Presentation thumbnail
Epicardial adipose tissue, functional status, and invasive exercise hemodynamics in heart failure with preserved ejection fraction: Insights from the REDUCE LAP-HF II trial.
Doctor T. Gorter (Groningen, NL)
Abstract Slides Video
Presentation thumbnail
Mid-term renal impact of SGLT2 inhibitors in heart failure: a systematic review and meta-analysis
Doctor A. Sinha (Birmingham, GB)
Abstract Slides Video
Presentation thumbnail
The effect of GLP-1 receptor agonists on obstructive sleep apnea in ambulatory patients with HFpEF, obesity, and type 2 diabetes.
Assistant Professor P. Kalaydzhiev (Sofia, BG)
Abstract Slides Video
Presentation thumbnail
Impact of Na+/glucose cotransporter 2 (SGLT2) inhibitor therapy on biventricular ventricular-arterial coupling in patients with heart failure with reduced ejection fraction
Miss C. Madaudo (Palermo, IT)
Abstract Slides Video
Presentation thumbnail
The effect of malnutrition on the efficacy and safety of empagliflozin: a post hoc analysis of the EMPEROR-Reduced trial
Doctor W. Li (Chengdu, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Targeting metabolism in heart failure

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Low-valine diet ameliorates pathological cardiac hypertrophy by inhibiting LONP1-mediated ATP5F1B degradation
thumbnail
Congress Presentation
Silencing of microRNA-106b-5p prevents doxorubicin-mediated cardiotoxicity through modulation of the PR55/YY1/sST2 signaling axis
thumbnail
Congress Presentation
The potential protective effect of dapagliflozin on the development of cardiotoxicity in cancer patients after two years of observation.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources